14 December 2010
Value for money?
A recent report compared the costs of newer anti-diabetic medications. This included glitazones, exenatide and gliptins. The cheapest of these costs about £400 a year per patient compared with under £10 for a sulphonylurea and under £20 for metformin.
The two important questions are :
1. Are the newer medications 20 times as good as metformin?
2. Is it better, purely on a cost basis, to treat twenty people with metformin or one person with a gliptin?